People: Array BioPharma Inc (ARRY.O)

ARRY.O on Consolidated Issue listed on NASDAQ Global Market

2.40USD
9 Feb 2010
Price Change (% chg)

$-0.01 (-0.41%)
Prev Close
$2.41
Open
$2.44
Day's High
$2.44
Day's Low
$2.35
Volume
250,779
Avg. Vol
437,794
52-wk High
$4.65
52-wk Low
$1.68

view people for:

Summary

Name Age Since Current Position
Lefkoff, Kyle 50 1998 Chairman of the Board
Conway, Robert 55 1999 Chief Executive Officer, Director
Koch, Kevin 49 1998 President, Chief Scientific Officer, Director
Carruthers, R. Michael 51 2002 Chief Financial Officer
Snitman, David 57 1998 Chief Operating Officer, Vice President - Business Development, Director
Moore, John 45 2002 Vice President, General Counsel, Secretary
Bergstrom, Bengt 2010 Vice President - Clinical Development
Bullock, Francis 72 1998 Director
Caruthers, Marvin 69 1998 Director
Zabriskie, John 70 2001 Director
Van Lunsen, Gil 67 2002 Director
Williams, Douglas 51 2004 Director
» Insider Trading

Biographies

Name Description
Lefkoff, Kyle Mr. Kyle A. Lefkoff has served as the Chairman of the Board of Directors of Array Biopharma Inc. since May 1998. Since 1995, Mr. Lefkoff has been a General Partner of Boulder Ventures Limited, a venture capital firm and a prior investor in the company. From 1986 until 1995, Mr. Lefkoff was employed by Colorado Venture Management, a venture capital firm. Mr. Lefkoff serves on the Board of Directors for a number of private companies, including: Barofold Inc., Centerstone Technologies, Inc., MiraGen Inc. and Trust Company of America. Mr. Lefkoff received a B.A. in economics from Vassar College and an M.B.A. from the University of Chicago.
Conway, Robert Mr. Robert E. Conway has served as Chief Executive Officer and a member of Board of Directors of Array Biopharma Inc. since November 1999. Prior to joining Array, Mr. Conway was the Chief Operating Officer and Executive Vice President of Hill Top Research, Inc. from 1996 to 1999. From 1979 until 1996, Mr. Conway held various executive positions for Corning, Inc., including Corporate Vice President and General Manager of Corning Hazleton, Inc., a preclinical contract research organization. Mr. Conway serves on the Board of Directors of DEMCO, Inc. and PRA International. In addition, Mr. Conway is a member of the Strategic Advisory Committee of Genstar Capital, LLC and is on the board of the Biotechnology Industry Organization. Mr. Conway received a B.S. in accounting from Marquette University and an M.B.A. from the University of Cincinnati.
Koch, Kevin Dr. Kevin Koch is a Co-Founder of Array Biopharma Inc. and has served as President, Chief Scientific Officer and a member of Board of Directors since May 1998. Prior to forming Array, Dr. Koch was an Associate Director of Medicinal Chemistry and Project Leader for the Protease Inhibitor and New Leads project teams for Amgen Inc. from 1995 to 1998. From 1988 until 1995, Dr. Koch held various positions with Pfizer Central Research, including Senior Research Investigator and Project Coordinator for the Cellular Migration and Immunology Project Teams. From 1998 to 2003, Dr. Koch was an elected board member of the Inflammation Research Association. Dr. Koch received a B.S. in chemistry and biochemistry from the State University of New York at Stony Brook and a Ph.D. in synthetic organic chemistry from the University of Rochester.
Carruthers, R. Michael Mr. R. Michael Carruthers has served as Chief Financial Officer of Array Biopharma Inc. since December 1998, and served as Secretary from December 1998 until October 2002. Prior to joining Array, Mr. Carruthers was Chief Financial Officer from October 1993 until December 1998 of Sievers Instrument, Inc. From May 1989 until October 1993, Mr. Carruthers was the treasurer and controller for the Waukesha division of Dover Corporation. Mr. Carruthers was previously employed as an accountant with Coopers & Lybrand, LLP. He currently serves on the Board of Directors of Pyxant Labs, a private company. Mr. Carruthers received a B.S. in accounting from the University of Colorado and an M.B.A. from the University of Chicago.
Snitman, David Dr. David L. Snitman is a Co-Founder of Array Biopharma Inc. and has served as Chief Operating Officer, Vice President of Business Development and a member of Board of Directors since May 1998. Prior to forming Array, Dr. Snitman held various positions with Amgen Inc. since December 1981, including Associate Director, New Products and Technology and Manager of Amgen's Boulder research facility. Dr. Snitman currently serves on the Board of Directors of privately-held Barofold Inc. Dr. Snitman received a B.S. in chemistry from Northeastern University and a Ph.D. in the synthesis of natural products from the University of Colorado, and was a National Institutes of Health Postdoctoral Fellow at the Massachusetts Institute of Technology.
Moore, John Mr. John R. Moore has served as Vice President and General Counsel of Array Biopharma Inc. since May 2002 and as Secretary since October 2002. Prior to joining Array, Mr. Moore was an associate for three years with the law firm of Wilson Sonsini Goodrich & Rosati where he negotiated transactions involving technology, intellectual property and products. From September 1992 to July 1996, and August 1996 to June 1999, Mr. Moore was an associate with the law firms of Kenyon & Kenyon and Arnold White & Durkee, respectively, where he focused on intellectual property matters. Mr. Moore received a J.D. from the University of North Carolina at Chapel Hill School of Law, a M.S. in Biochemistry from the University of Illinois at Urbana-Champaign and a B.S. in Chemistry from the University of North Carolina at Chapel Hill.
Bergstrom, Bengt Dr. Bengt Bergstrom M.D. is the Vice President - Clinical Development of Array BioPharma Inc. With over 30 years of experience as an M.D. / Ph.D. and more than 17 years working in the pharmaceutical industry, Dr. Bergstrom will lead Array's clinical science and drug safety activities for the Company's growing pipeline of targeted small molecule drugs to treat cancer and inflammatory diseases. Prior to joining Array, Dr. Bergstrom held various leadership positions within drug development, project management, strategic marketing and business development, and clinical sciences at Hoffmann-La Roche, most recently serving as Clinical Science Leader in oncology drug development. Over the years, he led programs for small molecules, biologics and gene therapy in various therapeutic areas including oncology, inflammation, diabetes, metabolism and neurology. He has experience with Phase 1 through 4 clinical trials and has worked with regulatory agencies around the world. He has worked on six approved New Drug Applications as well as several Investigational New Drug Applications. Dr. Bergstrom studied at the University of Lund in Sweden where he received his M.D. and Ph.D.
Bullock, Francis Dr. Francis J. Bullock has served as a member of Board of Directors of Array Biopharma Inc. since May 1998. Dr. Bullock is currently an independent consultant. From 2002 to 2003, Dr. Bullock was a Senior Advisor for the Strategic Decisions Group, a management consulting firm. From 1993 to 2002, Dr. Bullock was a senior consultant for Arthur D. Little, Inc., focused on pharmaceutical and biotechnology research and development, as well as the fine chemicals and agricultural chemicals industries. From 1981 to 1993, Dr. Bullock served as Senior Vice President, Research Operations at Schering-Plough Research Institute. Dr. Bullock serves on the board of publicly-traded GTC Biotherapeutics and Atherex, a privately-held company. Dr. Bullock received a B.S. in pharmacy from the Massachusetts College of Pharmacy, an A.M. in organic chemistry and a Ph.D. in organic chemistry from Harvard University.
Caruthers, Marvin Dr. Marvin H. Caruthers Ph.D. has served as a member of Board of Directors of Array Biopharma Inc. since August 1998. Since 1979, Dr. Caruthers has been a Distinguished Professor of Biochemistry and Chemistry at the University of Colorado, Boulder. Dr. Caruthers is a member of the National Academy of Sciences and the American Academy of Arts and Sciences and was previously a member of the Scientific Advisory Board of Amgen Inc. Dr. Carruthers serves on the Board of Directors of privately-held Barofold Inc. and MiraGen Inc. Dr. Caruthers received a B.S. in chemistry from Iowa State University and a Ph.D. in chemistry from Northwestern University.
Zabriskie, John Dr. John L. Zabriskie has served as a member of Board of Directors of Array Biopharma Inc. since January 2001. Dr. Zabriskie is Co-Founder and Director of Puretech Ventures, LLC, and the past Chairman of the Board, Chief Executive Officer and President of NEN Life Science Products, Inc., a supplier of kits for labeling and detection of DNA. Prior to joining NEN Life Science Products, Dr. Zabriskie was President and Chief Executive Officer of Pharmacia and Upjohn Inc. As Chairman of the Board and Chief Executive Officer of Upjohn, Dr. Zabriskie led the Upjohn project, which resulted in the $12 billion merger of equals with Pharmacia. Prior to joining Upjohn in 1994, Dr. Zabriskie was Executive Vice President for Merck & Co., Inc. Dr. Zabriskie currently serves on the boards of publicly-traded Kellogg Co. and ARCA biopharma Inc, and privately-held Protein Forest Inc. and Puretech Ventures. Dr. Zabriskie received his undergraduate degree in chemistry from Dartmouth College and his Ph.D. in organic chemistry from the University of Rochester.
Van Lunsen, Gil Mr. Gil J. Van Lunsen has served as a member of Board of Directors of Array Biopharma Inc. since October 2002. Prior to his retirement in June 2000, Mr. Van Lunsen was a Managing Partner of KPMG LLP and led the firm's Tulsa, Oklahoma office. During his 33-year career, Mr. Van Lunsen held various positions of increasing responsibility with KPMG and was elected to the partnership in 1977. Mr. Van Lunsen is currently a member of the Audit Committee at ONEOK Partners, L.P. in Tulsa, Oklahoma. Additionally, Mr. Van Lunsen was the Audit Committee Chairman at Sirenza Microdevices, Inc. and predecessor entities in Broomfield, Colorado, from July 2002 until December 2007. Mr. Van Lunsen received a B.S./B.A. in accounting from the University of Denver.
Williams, Douglas Dr. Douglas E. Williams has served as a member of Board of Directors Array Biopharma Inc. since April 2004. He currently serves as Chief Executive Officer of ZymoGenetics, Inc. From September 2003 to August 2004, Dr. Williams served as Seattle Genetics' Chief Scientific Officer, Executive Vice President and a member of their Board of Directors. Prior to joining Seattle Genetics, from November 2002 to August 2003, Dr. Williams was Head of Health and Strategic Development for Genesis Research & Development, a biotechnology company located in New Zealand. From July to October 2002, he served as Senior Vice President, Washington Site Leader and a member of the Executive Committee for Amgen Inc. Dr. Williams joined Amgen in July 2002 when it acquired Immunex Corporation, where he worked for 14 years, most recently serving as Executive Vice President, Chief Technology Officer and a member of Immunex's Board of Directors. Prior to his work at Immunex, Dr. Williams served on the faculty of the Indiana University School of Medicine and the Department of Laboratory Medicine at the Roswell Park Memorial Institute. He serves on the board of privately-held Aerovance, Inc., is a member of the Scientific Advisory Board of Symphony Capital and a member of the Board of Trustees of the Fred Hutchinson Cancer Research Center. Dr. Williams holds a B.S. magna cum laude in biological sciences from the University of Massachusetts, Lowell and a Ph.D. in physiology from the State University of New York at Buffalo, Roswell Park Division.

Basic Compensation

Name Fiscal Year Total
Lefkoff, Kyle --
Conway, Robert 1,312,180
Koch, Kevin 1,007,650
Carruthers, R. Michael 518,433
Snitman, David 739,236
Moore, John 551,897
Bergstrom, Bengt --
Bullock, Francis --
Caruthers, Marvin --
Zabriskie, John --
Van Lunsen, Gil --
Williams, Douglas --
As Of 29 Jun 2009

Options Compensation

Name Options Value
Lefkoff, Kyle 0 0
Conway, Robert 1,434,765 6,098,163
Koch, Kevin 678,533 1,474,592
Carruthers, R. Michael 346,082 1,095,177
Snitman, David 587,265 1,290,501
Moore, John 169,727 238,530
Bergstrom, Bengt 0 0
Bullock, Francis 0 0
Caruthers, Marvin 0 0
Zabriskie, John 0 0
Van Lunsen, Gil 0 0
Williams, Douglas 0 0

Insider Trading

Name Shares Traded Price
CARRUTHERS R MICHAEL 1,644 $2.49
BULLOCK FRANCIS J 10,000 $0.60
CARRUTHERS R MICHAEL 5,681 $2.69
CARRUTHERS R MICHAEL 1,533 $2.66
CARRUTHERS R MICHAEL 2,045 $2.01
KOCH KEVIN 28,863 $0.60
CARRUTHERS R MICHAEL 2,049 $2.01
CONWAY ROBERT E 125,324 $2.58
CONWAY ROBERT E 228,751 $0.60
MOORE JOHN R 20,067 $0.00
SNITMAN DAVID L 26,424 $0.00
CARRUTHERS R MICHAEL 18,706 $0.00
CONWAY ROBERT E 50,532 $0.00
MOORE JOHN R 1,250 $0.00
KOCH KEVIN 34,596 $0.00
CARRUTHERS R MICHAEL 1,315 $2.77
CARRUTHERS R MICHAEL 882 $4.17
CARRUTHERS R MICHAEL 925 $3.95
CARRUTHERS R MICHAEL 1,170 $3.06
CARRUTHERS R MICHAEL 1,170 $3.13
CARUTHERS MARVIN H 450,753 $0.00
CARUTHERS MARVIN H 450,753 $0.00
LEFKOFF KYLE 6,000 $0.00
LEFKOFF KYLE 6,000 $0.00
SNITMAN DAVID L 33,883 $0.24
» Full list on Insider Trading
view people for: